¬³¬à¬Ö¬Õ¬Ú¬ß¬Ö¬ß¬Ú¬Ö ¬Ü¬à¬Þ¬á¬Ñ¬ß¬Ú¬Û
¬ª¬ã¬ã¬Ý¬Ö¬Õ¬à¬Ó¬Ñ¬ß¬Ú¬ñ ¬Ú ¬Ú¬ã¬ã¬Ý¬Ö¬Õ¬à¬Ó¬Ñ¬ß¬Ú¬ñ
¬±¬â¬à¬Õ¬å¬Ü¬è¬Ú¬ñ
¬²¬Ñ¬Ù¬â¬Ñ¬Ò¬à¬ä¬Ü¬Ñ ¬ã¬í¬â¬î¬ñ
¬ª¬ã¬ã¬Ý¬Ö¬Õ¬à¬Ó¬Ñ¬ß¬Ú¬ñ ¬Ú ¬Ú¬ã¬ã¬Ý¬Ö¬Õ¬à¬Ó¬Ñ¬ß¬Ú¬ñ
PR
¬°¬Ò¬Ù¬à¬â ¬Ü¬à¬Þ¬á¬Ñ¬ß¬Ú¬Ú
¬Ú¬ã¬ä¬à¬â¬Ú¬ñ
¬ª¬ã¬á¬à¬Ý¬ß¬Ú¬ä¬Ö¬Ý¬î¬ß¬à¬Ö ¬Ó¬Ó¬Ö¬Õ¬Ö¬ß¬Ú¬Ö
¬ª¬ß¬Ó¬Ö¬ã¬ä¬Ú¬è¬Ú¬à¬ß¬ß¬Ñ¬ñ ¬à¬â¬Ô¬Ñ¬ß¬Ú¬Ù¬Ñ¬è¬Ú¬ñ
ExoSCRT Exosome
Regenerative Therapeutics
Immuno Oncology
ASCE+ Skin
ASCE+ Hair
Exomage
Celltweet
Lapuroon
Celosome
ExoBRID-E
Vexosome
Rose Exosome
‡„Š…§Š
¬¢¬å¬Þ¬Ñ¬Ô¬Ñ
¬±¬â¬Ñ¬Ó¬Ú¬ä¬Ö¬Ý¬î¬ã¬ä¬Ó¬Ö¬ß¬ß¬í¬Ö ¬Ù¬Ñ¬Õ¬Ñ¬é¬Ú
¬¬¬à¬â¬Ö¬ñ PR
¬©¬Ñ¬â¬å¬Ò¬Ö¬Ø¬ß¬í¬Û PR
¬£¬ß¬å¬ä¬â¬Ö¬ß¬ß¬Ú¬Û ¬¯¬à¬Ó¬à¬ã¬ä¬Ú
¬Õ¬à¬Þ¬à¬Û
1:1 ¬Ù¬Ñ¬á¬â¬à¬ã
¬Á¬©¬½¬¬
KOR
ENG
RUS
¬³¬à¬Ö¬Õ¬Ú¬ß¬Ö¬ß¬Ú¬Ö ¬Ü¬à¬Þ¬á¬Ñ¬ß¬Ú¬Û
¬°¬Ò¬Ù¬à¬â ¬Ü¬à¬Þ¬á¬Ñ¬ß¬Ú¬Ú
¬Ú¬ã¬ä¬à¬â¬Ú¬ñ
¬ª¬ã¬á¬à¬Ý¬ß¬Ú¬ä¬Ö¬Ý¬î¬ß¬à¬Ö ¬Ó¬Ó¬Ö¬Õ¬Ö¬ß¬Ú¬Ö
¬ª¬ß¬Ó¬Ö¬ã¬ä¬Ú¬è¬Ú¬à¬ß¬ß¬Ñ¬ñ ¬à¬â¬Ô¬Ñ¬ß¬Ú¬Ù¬Ñ¬è¬Ú¬ñ
R & D
ExoSCRT Exosome
Regenerative Therapeutics
Immuno Oncology
¬ä¬à¬Ó¬Ñ¬â
ASCE+ Skin
ASCE+ Hair
Exomage
Celltweet
Lapuroon
Celosome
¬²¬Ñ¬Ù¬â¬Ñ¬Ò¬à¬ä¬Ü¬Ñ ¬ã¬í¬â¬î¬ñ
ExoBRID-E
Vexosome
Rose Exosome
¬ª¬ã¬ã¬Ý¬Ö¬Õ¬à¬Ó¬Ñ¬ß¬Ú¬Ö ¬á¬â¬à¬Ú¬Ù¬Ó¬à¬Õ¬Ú¬ä¬Ö¬Ý¬î¬ß¬à¬ã¬ä¬Ú
‡„Š…§Š
¬¢¬å¬Þ¬Ñ¬Ô¬Ñ
¬©¬Ñ¬Õ¬Ñ¬é¬Ñ ¬á¬â¬Ñ¬Ó¬Ú¬ä¬Ö¬Ý¬î¬ã¬ä¬Ó¬Ñ
PR
¬¬¬à¬â¬Ö¬ñ PR
¬©¬Ñ¬â¬å¬Ò¬Ö¬Ø¬ß¬í¬Û PR
¬£¬ß¬å¬ä¬â¬Ö¬ß¬ß¬Ú¬Û ¬¯¬à¬Ó¬à¬ã¬ä¬Ú
KOR
ENG
RUS
¬³¬à¬Ö¬Õ¬Ú¬ß¬Ö¬ß¬Ú¬Ö ¬Ü¬à¬Þ¬á¬Ñ¬ß¬Ú¬Û
¬°¬Ò¬Ù¬à¬â ¬Ü¬à¬Þ¬á¬Ñ¬ß¬Ú¬Ú
¬Ú¬ã¬ä¬à¬â¬Ú¬ñ
¬ª¬ã¬á¬à¬Ý¬ß¬Ú¬ä¬Ö¬Ý¬î¬ß¬à¬Ö ¬Ó¬Ó¬Ö¬Õ¬Ö¬ß¬Ú¬Ö
¬ª¬ß¬Ó¬Ö¬ã¬ä¬Ú¬è¬Ú¬à¬ß¬ß¬Ñ¬ñ ¬à¬â¬Ô¬Ñ¬ß¬Ú¬Ù¬Ñ¬è¬Ú¬ñ
R & D
ExoSCRT Exosome
Regenerative Therapeutics
Immuno Oncology
¬ä¬à¬Ó¬Ñ¬â
ASCE+ Skin
ASCE+ Hair
Exomage
Celltweet
Lapuroon
Celosome
¬²¬Ñ¬Ù¬â¬Ñ¬Ò¬à¬ä¬Ü¬Ñ ¬ã¬í¬â¬î¬ñ
ExoBRID-E
Vexosome
Rose Exosome
¬ª¬ã¬ã¬Ý¬Ö¬Õ¬à¬Ó¬Ñ¬ß¬Ú¬Ö ¬á¬â¬à¬Ú¬Ù¬Ó¬à¬Õ¬Ú¬ä¬Ö¬Ý¬î¬ß¬à¬ã¬ä¬Ú
‡„Š…§Š
¬¢¬å¬Þ¬Ñ¬Ô¬Ñ
¬©¬Ñ¬Õ¬Ñ¬é¬Ñ ¬á¬â¬Ñ¬Ó¬Ú¬ä¬Ö¬Ý¬î¬ã¬ä¬Ó¬Ñ
PR
¬¬¬à¬â¬Ö¬ñ PR
¬Ù¬Ñ ¬â¬å¬Ò¬Ö¬Ø¬à¬Þ PR
¬¯¬à¬Ó¬à¬ã¬ä¬Ú ¬Ü¬à¬Þ¬á¬Ñ¬ß¬Ú¬Ú
Bio ingredient
VEXOSOME¢â
scroll
ExoBRID-E
Vexosome
Rose Exosome
Vexosome
¬¤¬Ú¬Ò¬â¬Ú¬Õ¬ß¬í¬Ö ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬í
01
Vexosome¢â Solution
ÇǺÎÁö¹æ»ý¼º¿¡ µµ¿òÀ» ÁÖ´Â »çÆ÷°Ô´Ñ·ùÀÇ µð¿À½º°Ô´Ñ°ú EXOSOMEÀ» °áÇÕ½ÃŲ ¿ø·áÀÔ´Ï´Ù.
À¯È°úÁ¤À» ÅëÇØ µð¿À½º°Ô´ÑÀ» ÇÏÀ̵å·ÎÁ¦³×ÀÌƼµå·¹½Ãƾ¿¡ Æ÷Áý ½ÃÄ×°í EXOSOMEÀÇ ±ÕÁúȸ¦ ÅëÇØ ÇǺΠÈí¼ö¿¡ ¿ëÀÌÇÑ ÇüÅ·ΠÁ¦Á¶ÇÏ¿´½À´Ï´Ù.
¬¹¬ä¬à ¬ä¬Ñ¬Ü¬à¬Ö Vexosome ?
¬¥¬Ý¬ñ ¬á¬â¬Ú¬Õ¬Ñ¬ß¬Ú¬ñ ¬Ü¬à¬Ø¬Ö ¬ï¬Ý¬Ñ¬ã¬ä¬Ú¬é¬ß¬à¬ã¬ä¬Ú ¬Ú ¬å¬Ó¬Ö¬Ý¬Ú¬é¬Ö¬ß¬Ú¬ñ ¬à¬Ò¬ì¬Ö¬Þ¬Ñ ¬á¬å¬ä¬Ö¬Þ ¬ã¬à¬é¬Ö¬ä¬Ñ¬ß¬Ú¬ñ ¬à¬Ò¬ì¬Ö¬Þ¬ß¬à¬Ô¬à ¬ã¬í¬â¬î¬ñ ¬Õ¬Ý¬ñ ¬Ü¬à¬Ø¬Ú ¬ã ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬à¬Û ¬Ú¬Ù ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü ¬Ó¬í¬ã¬à¬Ü¬à¬Û ¬é¬Ú¬ã¬ä¬à¬ä¬í 0,1 ~ 0,5%
¬¿¬ä¬à ¬Ò¬à¬Ý¬Ö¬Ö ¬ï¬æ¬æ¬Ö¬Ü¬ä¬Ú¬Ó¬ß¬í¬Û ¬Ú ¬Ò¬Ö¬Ù¬à¬á¬Ñ¬ã¬ß¬í¬Û ¬á¬Ñ¬ä¬Ö¬ß¬ä¬ß¬í¬Û ¬Ú¬ß¬Ô¬â¬Ö¬Õ¬Ú¬Ö¬ß¬ä.
Vexosome
¬¬¬à¬ã¬Þ¬Ö¬ä¬Ú¬é¬Ö¬ã¬Ü¬à¬Ö ¬ã¬í¬â¬î¬Ö ¬Ú ¬á¬Ñ¬ä¬Ö¬ß¬ä¬ß¬Ñ¬ñ ¬â¬Ö¬Ô¬Ú¬ã¬ä¬â¬Ñ¬è¬Ú¬ñ ¬ã¬ä¬Ñ¬ä¬å¬ã¬Ñ
Exosome, ¬ß¬à¬Ó¬í¬Û ¬Ò¬Ú¬à ¬Ü¬à¬Þ¬á¬à¬ß¬Ö¬ß¬ä ¬â¬Ö¬Ô¬Ö¬ß¬Ö¬â¬Ñ¬ä¬Ú¬Ó¬ß¬à¬Û ¬ï¬ã¬ä¬Ö¬ä¬Ú¬Ü¬Ú,
¬à¬Ò¬Ö¬ã¬á¬Ö¬é¬Ú¬Ó¬Ñ¬Ö¬ä ¬Ö¬ã¬ä¬Ö¬ã¬ä¬Ó¬Ö¬ß¬ß¬à¬Ö ¬Ù¬Õ¬à¬â¬à¬Ó¬î¬Ö ¬Ü¬à¬Ø¬Ú.
¬´¬Ö¬ç¬ß¬à¬Ý¬à¬Ô¬Ú¬ñ ExoBRID
¬°¬á¬ä¬Ú¬Þ¬Ñ¬Ý¬î¬ß¬Ñ¬ñ ¬ä¬Ö¬ç¬ß¬à¬Ý¬à¬Ô¬Ú¬ñ ¬â¬Ñ¬Ù¬â¬Ñ¬Ò¬à¬ä¬Ü¬Ú ¬Ü¬à¬ã¬Þ¬Ö¬ä¬Ú¬é¬Ö¬ã¬Ü¬Ú¬ç ¬Ú¬ß¬Ô¬â¬Ö¬Õ¬Ú¬Ö¬ß¬ä¬à¬Ó ¬ß¬Ñ ¬à¬ã¬ß¬à¬Ó¬Ö ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ ¬Ò¬Ú¬à¬Ô¬Ú¬Ò¬â¬Ú¬Õ¬ß¬í¬Þ ¬Þ¬Ö¬ä¬à¬Õ¬à¬Þ